Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA‐20b‐3p/DEPDC1 axis

6 Oct 2022

Abstract excerpt

Oxaliplatin (L-OHP) is a standard treatment drug for colorectal cancer (CRC), but acquired drug resistance limits the outcome of patients. We investigated the involvement of sirtuin 1 (SIRT1) in L-OHP resistance in the setting of CRC via microRNA-20b-3p/DEP domain containing 1 (miR-20b-3p/DEPDC1) axis. CRC tissues that were resistant or sensitive to L-OHP were harvested, in which SIRT1, miR-20b-3p, and DEPDC1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cancer-related molecular mechanisms research
Share to Sirtuins and Resveratrol in Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36200529
DOI: 10.1002/cbin.11905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA‐20b‐3p/DEPDC1 axisPMID 36200529Read ↗

ABCC10-Mediated Oxaliplatin Resistance in Colorectal Cancer Was Alleviated by Intense Endoplasmic Reticulum Stress (ERS) / IRE1αSemantic proximity Read ↗

Restoring miR-145 overcome oxaliplatin resistance by targeting the ABCC1 gene and re-establishing drug-induced anti-cancer effects in colorectal cancerSemantic proximity Read ↗

SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axisSemantic proximity Read ↗

miR-100-5p Enhanced Cell Cycle-mediated Chemoresistance Through Modulating CTDSPL/pRB/E2F1 Signaling Pathway in Oxaliplatin-Resistant Colorectal CancerSemantic proximity Read ↗

The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.Semantic proximity Read ↗

Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axisSemantic proximity Read ↗

In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated Topoisomerase Drug Resistance in Human Colorectal Cancer CellsSemantic proximity Read ↗

G9a/GLP inhibitor UNC0642 induces growth arrest in colorectal cancer via induction of ROS generation, coordinated overexpression of GADD genes, and the JNK/p38 MAPK pathwaySemantic proximity Read ↗

SENP1 participates in Irinotecan resistance in human colon cancer cellsSemantic proximity Read ↗

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read ↗

The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro studySemantic proximity Read ↗

Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.